Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir

Novel integrase inhibitors are in advanced clinical development, and cross-resistance data are needed to consider the possibility to plan a sequential usage within this class of antiretroviral drugs. Ex vivo phenotypic assays were conducted on 11 wild-type and 27 fully replicating recombinant viruse...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases Jg. 204; H. 11; S. 1811
Hauptverfasser:	Canducci, Filippo, Ceresola, Elisa R, Boeri, Enzo, Spagnuolo, Vincenzo, Cossarini, Francesca, Castagna, Antonella, Lazzarin, Adriano, Clementi, Massimo
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.12.2011
Schlagworte:	Amino Acid Substitution - genetics Anti-HIV Agents - pharmacology Drug Resistance, Viral - genetics Heterocyclic Compounds, 3-Ring - pharmacology HIV Infections - drug therapy HIV Infections - virology HIV Integrase - genetics HIV Integrase Inhibitors - pharmacology HIV-1 - drug effects HIV-1 - enzymology HIV-1 - genetics Humans Inhibitory Concentration 50 Microbial Sensitivity Tests Mutation Phenotype Pyrrolidinones - pharmacology Raltegravir Potassium
ISSN:	1537-6613, 1537-6613
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!